These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28025970)

  • 41. Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis.
    Yang J; Chen Y; Li X; Wei X; Chen X; Zhang L; Zhang Y; Xu Q; Wang H; Li Y; Lu C; Chen W; Zeng C; Yin T
    Int J Cardiol; 2013 Oct; 168(4):4234-43. PubMed ID: 23932037
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation.
    Santos PC; Dinardo CL; Schettert IT; Soares RA; Kawabata-Yoshihara L; Bensenor IM; Krieger JE; Lotufo PA; Pereira AC
    Eur J Clin Pharmacol; 2013 Apr; 69(4):789-97. PubMed ID: 22990331
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of gamma-glutamyl carboxylase gene polymorphisms on warfarin dose requirement: a systematic review and meta-analysis.
    Sun Y; Wu Z; Li S; Qin X; Li T; Xie L; Deng Y; Chen J
    Thromb Res; 2015 Apr; 135(4):739-47. PubMed ID: 25681132
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacogenetics of oral anticoagulants: a basis for dose individualization.
    Stehle S; Kirchheiner J; Lazar A; Fuhr U
    Clin Pharmacokinet; 2008; 47(9):565-94. PubMed ID: 18698879
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.
    Scott SA; Jaremko M; Lubitz SA; Kornreich R; Halperin JL; Desnick RJ
    Pharmacogenomics; 2009 Aug; 10(8):1243-55. PubMed ID: 19663669
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.
    Yuan HY; Chen JJ; Lee MT; Wung JC; Chen YF; Charng MJ; Lu MJ; Hung CR; Wei CY; Chen CH; Wu JY; Chen YT
    Hum Mol Genet; 2005 Jul; 14(13):1745-51. PubMed ID: 15888487
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis.
    Takeuchi M; Kobayashi T; Biss T; Kamali F; Vear SI; Ho RH; Bajolle F; Loriot MA; Shaw K; Carleton BC; Hamberg AK; Wadelius M; Hirono K; Taguchi M; Wakamiya T; Yanagimachi M; Hirai K; Itoh K; Brandão LR; Ito S
    Pharmacogenomics J; 2020 Apr; 20(2):306-319. PubMed ID: 31673144
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical significance of combined CYP2C9 and VKORC1 genotypes in Japanese patients requiring warfarin.
    Miyagata Y; Nakai K; Sugiyama Y
    Int Heart J; 2011; 52(1):44-9. PubMed ID: 21321468
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.
    Cen HJ; Zeng WT; Leng XY; Huang M; Chen X; Li JL; Huang ZY; Bi HC; Wang XD; He YL; He F; Zhou RN; Zheng QS; Zhao LZ
    Br J Clin Pharmacol; 2010 Aug; 70(2):234-40. PubMed ID: 20653676
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
    Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
    Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of Genetic Polymorphisms in the VKORC1 and CYP2C9 Genes with Warfarin Dosage in a Group of Kuwaiti Individuals.
    Alrashid MH; Al-Serri A; Alshemmari SH; Koshi P; Al-Bustan SA
    Mol Diagn Ther; 2016 Apr; 20(2):183-90. PubMed ID: 26940072
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Frequency of Common VKORC1 Polymorphisms and Their Impact on Warfarin Dose Requirement in Pakistani Population.
    Qayyum A; Najmi MH; Mansoor Q; Irfan M; Naveed AK; Hanif A; Kazmi AR; Ismail M
    Clin Appl Thromb Hemost; 2018 Mar; 24(2):323-329. PubMed ID: 27879469
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.
    Rusdiana T; Araki T; Nakamura T; Subarnas A; Yamamoto K
    Eur J Clin Pharmacol; 2013 Mar; 69(3):395-405. PubMed ID: 22855348
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.
    Ye C; Jin H; Zhang R; Sun Y; Wang Z; Sun W; Sun W; Peng Q; Liu R; Huang Y
    J Int Med Res; 2014 Feb; 42(1):67-76. PubMed ID: 24287930
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Influence of APOE Gene Polymorphism on Interindividual and Interethnic Warfarin Dosage Requirement: A Systematic Review and Meta-Analysis.
    Yu WY; Sun X; Wadelius M; Huang L; Peng C; Ma WL; Yang GP
    Cardiovasc Ther; 2016 Oct; 34(5):297-307. PubMed ID: 27062534
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
    Miao L; Yang J; Huang C; Shen Z
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nutri-pharmacogenomics of warfarin anticoagulation therapy: VKORC1 genotype-dependent influence of dietary vitamin K intake.
    Saito R; Takeda K; Yamamoto K; Nakagawa A; Aoki H; Fujibayashi K; Wakasa M; Motoyama A; Iwadare M; Ishida R; Fujioka N; Tsuchiya T; Akao H; Kawai Y; Kitayama M; Kajinami K
    J Thromb Thrombolysis; 2014 Jul; 38(1):105-14. PubMed ID: 23928870
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations.
    Gan GG; Phipps ME; Lee MM; Lu LS; Subramaniam RY; Bee PC; Chang SH
    Ann Hematol; 2011 Jun; 90(6):635-41. PubMed ID: 21110192
    [TBL] [Abstract][Full Text] [Related]  

  • 59. To establish a model for the prediction of initial standard and maintenance doses of warfarin for the Han Chinese population based on gene polymorphism: a multicenter study.
    Xia X; Huang N; Li B; Li Y; Zou L; Yuan D; Huang B; Bei Y; Liu Y; Fu J; Wu T; Chen W; Jiang S; Lv M; Zhang J
    Eur J Clin Pharmacol; 2022 Jan; 78(1):43-51. PubMed ID: 34453556
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.
    Tham LS; Goh BC; Nafziger A; Guo JY; Wang LZ; Soong R; Lee SC
    Clin Pharmacol Ther; 2006 Oct; 80(4):346-55. PubMed ID: 17015052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.